MentionFox
Home › Executive changes › ClearPoint Neuro, Inc.
Leadership changes · CLPT · SEC Form 8-K, Item 5.02

Leadership changes at ClearPoint Neuro, Inc. (2026)

Before you join, sell to or invest in ClearPoint Neuro, Inc.

MentionFox check on ClearPoint Neuro, Inc.: only 1 source on file so far (checked 15 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/clearpoint-neuro

Check ClearPoint Neuro, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about ClearPoint Neuro, Inc.?

Who joined and who left ClearPoint Neuro, Inc. (CLPT)? 1 appointment reported on 2026-05-21, each cited to the company's own filing.

R. John Fletcher was named Chairman of the Board of ClearPoint Neuro, Inc. As of November 15, 2026, ClearPoint Neuro, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 21, 2026, naming 1 appointment (Form 8-K, May 21, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

MAK CAPITAL ONE LLC also filed stake reports on 3 other companies ↓

Sell to companies like ClearPoint Neuro, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-05-21

ClearPoint Neuro, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-21. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as ClearPoint Neuro, Inc. files it.

Also on the record for ClearPoint Neuro, Inc.

DateRecordFigureOur pageSource
November 3, 2026Stake report, Schedule 13G/A, by Bigger Michael8.12% of the class5%+ stakesSource
August 12, 2026Stake report, Schedule 13G/A, by MAK CAPITAL ONE LLC7.8% of the class5%+ stakesSource
August 4, 2026Stake report, Schedule 13G/A, by Bigger Michael7.45% of the class5%+ stakesSource
July 27, 2026Stake report, Schedule 13G/A, by BlackRock, Inc.7.1% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by MAK Capital Fund LP6.3% of the class5%+ stakesSource
April 20, 2026Stake report, Schedule 13G/A, by Bigger Michael7.54% of the class5%+ stakesSource
March 26, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
March 13, 2026Stake report, Schedule 13G, by MAK Capital Fund LP6.1% of the class5%+ stakesSource
February 5, 2026Form D, private offering$17.89M soldForm D pageSource
February 4, 2026Stake report, Schedule 13G/A, by Bigger Michael7.8% of the class5%+ stakesSource
November 12, 2025Stake report, Schedule 13G/A, by Bigger Michael7.6% of the class5%+ stakesSource
August 4, 2025Stake report, Schedule 13G/A, by Bigger Michael7.7% of the class5%+ stakesSource

Selling to them or working with them? See who runs ClearPoint Neuro, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on ClearPoint Neuro, Inc. and the records around it.

ClearPoint Neuro, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on ClearPoint Neuro, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on ClearPoint Neuro, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on ClearPoint Neuro, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 14 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-05-21InChairman of the Board8-K, 2026-05-21

Who leads ClearPoint Neuro, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to ClearPoint Neuro, Inc.?

New leaders reset buying decisions — get the Full Report on ClearPoint Neuro, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch ClearPoint Neuro, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Chairman of the Board at ClearPoint Neuro, Inc., with the record behind each one.

Find candidates like Chairman of the Board at ClearPoint Neuro, Inc.

Every change, in the filing's words

Filed 2026-05-21 · 8-K

Appointed: R. John Fletcher, Chairman of the Board

The Board also confirmed the appointment of Mr. Fletcher as Chairman of the Board.

Also stated in this filing

  • The annual meeting of the stockholders of ClearPoint Neuro, Inc. (the "Company") was held on May 20, 2026 (the "Annual Meeting").
  • At the Annual Meeting, the Company's stockholders voted to approve the adoption of the ClearPoint Neuro, Inc. Seventh Amended and Restated 2013 Incentive Compensation Plan (the "Plan").
  • The Company's Board of Directors (the "Board") had previously adopted and approved the Plan, subject to stockholder approval.
  • Following the Annual Meeting, the Board appointed the following committee memberships, effective upon the conclusion of the Annual Meeting and the resulting change in Board composition: Audit Committee: Lynnette C. Fallon (Chair), R. John Fletcher, and Timothy T. Richards.
  • The Board determined that each member qualifies as independent under Rule 5605(d)(2)(A) of the Nasdaq Marketplace Rules and as a "non-employee director" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.
  • Corporate Governance and Nominating Committee: R. John Fletcher (Chair), Lynnette C. Fallon, and B. Kristine Johnson.
  • The Board determined that each member qualifies as independent under Rule 5605(e)(1) of the Nasdaq Marketplace Rules.

Tools for this story

Each opens in a new tab, filled in for ClearPoint Neuro, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/clearpoint-neuro
Last updated 2026-11-15
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
ClearPoint Neuro, Inc. names R. John Fletcher Chair (2026). MentionFox, 2026-11-15. https://mentionfox.com/executive-changes/clearpoint-neuro